ORIC Pharmaceuticals, Inc. (ORIC)
Automate Your Wheel Strategy on ORIC
With Tiblio's Option Bot, you can configure your own wheel strategy including ORIC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ORIC
- Rev/Share 0.0075
- Book/Share 3.0931
- PB 3.233
- Debt/Equity 0.0
- CurrentRatio 12.0016
- ROIC -0.651
- MktCap 852242000.0
- FreeCF/Share -1.6326
- PFCF -7.3482
- PE -5.3471
- Debt/Assets 0.0
- DivYield 0
- ROE -0.5114
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ORIC | Stifel | -- | Buy | -- | $20 | Sept. 6, 2024 |
News
All You Need to Know About Oric Pharmaceuticals (ORIC) Rating Upgrade to Buy
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Oric Pharmaceuticals (ORIC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Does Oric Pharmaceuticals (ORIC) Have the Potential to Rally 104.99% as Wall Street Analysts Expect?
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 105% upside potential for Oric Pharmaceuticals (ORIC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
What Makes Oric Pharmaceuticals, Inc. (ORIC) a Strong Momentum Stock: Buy Now?
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Oric Pharmaceuticals, Inc. (ORIC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Wall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals (ORIC): Here's What You Should Know
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 131.3% upside potential for Oric Pharmaceuticals (ORIC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
ORIC Pharmaceuticals stock rises 20% pre-market on early data showing strong PSA responses and tolerability for prostate cancer drug ORIC-944 in phase Ib study.
Read More
About ORIC Pharmaceuticals, Inc. (ORIC)
- IPO Date 2020-04-24
- Website https://www.oricpharma.com
- Industry Biotechnology
- CEO Dr. Jacob M. Chacko M.B.A., M.D.
- Employees 122